WO2012141256A1 - Method for activating good intestinal bacterium, and composition for activating good intestinal bacterium - Google Patents

Method for activating good intestinal bacterium, and composition for activating good intestinal bacterium Download PDF

Info

Publication number
WO2012141256A1
WO2012141256A1 PCT/JP2012/060048 JP2012060048W WO2012141256A1 WO 2012141256 A1 WO2012141256 A1 WO 2012141256A1 JP 2012060048 W JP2012060048 W JP 2012060048W WO 2012141256 A1 WO2012141256 A1 WO 2012141256A1
Authority
WO
WIPO (PCT)
Prior art keywords
oligosaccharides
good
raffinose
activating
bacteria
Prior art date
Application number
PCT/JP2012/060048
Other languages
French (fr)
Japanese (ja)
Inventor
勝寿 木下
麻子 堀川
Original Assignee
株式会社北の達人コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社北の達人コーポレーション filed Critical 株式会社北の達人コーポレーション
Priority to JP2013509964A priority Critical patent/JP6328422B2/en
Publication of WO2012141256A1 publication Critical patent/WO2012141256A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Definitions

  • the present invention relates to a method for activating good enterobacteria, a method for improving intestinal flora by activating good enterobacteria, and an enteric good bacteria activating composition.
  • Intestinal bacteria that are permanently present in the human intestine have an important relationship with human health.
  • Bifidobacteria which is a representative of enterobacterium good bacteria, is known to have an intestinal action such as prevention and treatment of diarrhea and constipation, and an effect of inhibiting the growth of harmful bacteria in the intestine.
  • the proportion of various intestinal flora in the intestinal flora varies from individual to individual, and also varies depending on factors such as age, nutritional components, and stress.
  • bifidobacteria tend to decrease due to disease and aging
  • Conventionally there is a method of ingesting bifidobacteria in foods obtained by adding bifidobacteria to dairy products.
  • bifidobacteria are ingested orally, it is difficult to supply the bifidobacteria that have survived to the intestines, and the desired intestinal regulation effect cannot always be sufficiently obtained in many cases.
  • Patent Document 1 discloses a bread containing an oligosaccharide.
  • Patent Document 2 discloses a feed containing raffinose.
  • oligosaccharides have common properties such as being not degraded by human digestive enzymes, not being absorbed from the intestinal tract, and being selectively assimilated by bifidobacteria. However, these oligosaccharides are not necessarily selectively used only for good bacteria such as bifidobacteria, and there are bad bacteria that proliferate using oligosaccharides. When each of the above oligosaccharides is added to food or the like and taken orally, the oligosaccharides have only exhibited their characteristics. In addition, there are individual differences in which oligosaccharides exert the intestinal regulating effect, and ingestion of unsuitable oligosaccharides may cause side effects such as diarrhea.
  • oligosaccharides vary greatly in the degree of utilization by good bacteria and bad bacteria depending on the type thereof, and a satisfactory improvement effect on intestinal bacterial flora may not always be obtained.
  • the actual situation is that a method for improving the intestinal microflora having individual differences and obtaining a highly effective intestinal regulating action has not been established.
  • an object of the present invention is to provide a method for activating good enterobacteria and a composition for activating good enterobacteria to improve the intestinal flora.
  • the present invention relates to the following inventions.
  • ⁇ 1> Select a plurality of oligosaccharides suitable for the activation of the beneficial enteric bacteria, and combine the plurality of oligosaccharides at a blending ratio suitable for the activation of the enteric good bacteria to give to the intestinal flora A method for activating good intestinal bacteria.
  • ⁇ 2> The intestine according to ⁇ 1>, wherein the plurality of oligosaccharides are two or more selected from the group consisting of lactose, raffinose, lactulose, cellooligosaccharide, xylooligosaccharide, fructooligosaccharide, isomaltooligosaccharide, and galactooligosaccharide. How to activate Uchizen good bacteria.
  • ⁇ 3> The method for activating good enterobacteria according to ⁇ 1>, wherein the plurality of oligosaccharides is a combination of lactose, raffinose and cellooligosaccharide.
  • ⁇ 4> The method for activating good enterobacteria according to ⁇ 1>, wherein the plurality of oligosaccharides is a combination of raffinose, lactulose and cellooligosaccharide.
  • ⁇ 5> The method for activating good enterobacteria according to ⁇ 1>, wherein the plurality of oligosaccharides is a combination of lactose, raffinose, lactulose and cellooligosaccharide.
  • ⁇ 6> The method for activating good enteric bacteria according to ⁇ 1>, wherein the plurality of oligosaccharides are lactose, raffinose, lactulose, cellooligosaccharide, xylooligosaccharide, fructooligosaccharide, isomaltoligosaccharide, and galactooligosaccharide.
  • An intestine containing a mixture of a plurality of oligosaccharides suitable for activating good enteric bacteria in a target, and a combination of the plurality of oligosaccharides combined in a proportion suitable for activating the enteric good bacteria A good bacteria activation composition.
  • oligosaccharides are two or more selected from the group consisting of lactose, raffinose, lactulose, cellooligosaccharide, xylooligosaccharide, fructooligosaccharide, isomaltooligosaccharide, and galactooligosaccharide.
  • Uchizen good bacteria activation composition Uchizen good bacteria activation composition.
  • the plurality of oligosaccharides is a combination of lactose, raffinose, lactulose, and cellooligosaccharide.
  • oligosaccharides are lactose, raffinose, lactulose, cellooligosaccharide, xylooligosaccharide, fructooligosaccharide, isomaltoligosaccharide, and galactooligosaccharide.
  • the activation method of the enterobacterium good bacteria which can obtain the improvement effect with respect to the intestinal microflora from which environment differs according to individual differences, physical condition, age, etc., and an enterobacterium good bacteria activation composition Is done.
  • the method for activating good enteric bacteria of the present invention selects a plurality of oligosaccharides suitable for the activation of good enteric bacteria, and the blending ratio of the plurality of oligosaccharides suitable for the activation of the good enteric bacteria It is characterized by being given to the intestinal flora in combination.
  • the composition for activating good enteric bacteria of the present invention uses the above-mentioned method for activating good enteric bacteria, selects a plurality of oligosaccharides suitable for activating the target enteric good bacteria, It is characterized by containing the mixture which combined these oligosaccharides with the mixture ratio suitable for activation of the said enteric good bacteria.
  • the “intestinal good bacteria” are useful microorganisms in the human digestive tract, and specific examples include bifidobacteria and lactic acid bacteria.
  • the method for activating enteric good bacteria in the present invention is particularly bifidos. Suitable for activating bacteria.
  • the method for activating the enteric good bacteria is based on the original theory EOS theory developed by the present inventors.
  • the EOS theory uses Enterobacteria Oligosaccharide Synergy, and more specifically, it is the optimal bifidobacterial growth factor for the type of bifidobacteria that is representative of useful bacteria in the intestinal flora. This is a theory that creates a synergistic effect by selecting and mixing various oligosaccharides and maximizing the growth effect of the entire bifidobacteria.
  • the oligosaccharides complement each other, and the bifidobacteria inhabiting the intestine are used without waste, which is more effective than using the oligosaccharide alone.
  • the intestinal bacterial flora including other enteric good bacteria such as other bifidobacteria and lactic acid bacteria
  • this effect is not recognized in the human intestine in the combination of saccharides that do not include the oligosaccharide that is the subject of the present invention, such as glucose and sucrose, and is unique to the combination of a plurality of oligosaccharides based on the EOS theory. It is an effect. Therefore, taking or ingesting multiple oligosaccharides based on the method of activating good enterobacterium in EOS theory is very effective in that it can be used safely and with little risk of side effects. .
  • the oligosaccharide that can be used in the present invention is not particularly limited.
  • a commercially available product can be used, or a purified product separated and purified from an extract of a natural product containing the oligosaccharide can be used.
  • These oligosaccharides may be in any form such as powder, liquid or syrup, but are usually powder or syrup from the viewpoint of handling.
  • oligosaccharides since the effect of improving the intestinal microflora is particularly recognized, 2 selected from the group consisting of lactose, raffinose, lactulose, cellooligosaccharide, xylooligosaccharide, fructooligosaccharide, isomaltoligosaccharide and galactooligosaccharide 2 It is preferable to use more than one species. These oligosaccharides reach the intestine without being digested and absorbed in the human digestive tract, and are highly effective in proliferating good intestinal bacteria (bifidobacteria, lactic acid bacteria, etc.).
  • oligosaccharides The selection and blending ratio of oligosaccharides are determined based on the EOS theory.
  • raffinose has a high ratio of giving an intestinal regulating action to a subject. Therefore, it is preferable to include raffinose, and it has no ability to assimilate raffinose or has a weak ability to assimilate raffinose.
  • raffinose as a base, when the total amount is 100 wt%, raffinose is 1 wt% to 80 wt% (preferably 3 to 60 wt%), and other oligosaccharides are 70 wt% to 99% by weight (preferably 40 to 97% by weight).
  • a suitable combination of oligosaccharides to which the EOS theory can be applied is a combination of lactose, raffinose and cellooligosaccharide.
  • oligosaccharide combinations to which the EOS theory can be applied are raffinose, lactulose and cellooligosaccharide combinations.
  • oligosaccharide combinations to which the EOS theory can be applied are combinations of lactose, raffinose, lactulose and cellooligosaccharide.
  • oligosaccharide combinations to which the EOS theory can be applied are combinations of lactose, raffinose, lactulose, cellooligosaccharides, xylooligosaccharides, fructooligosaccharides, isomaltoligosaccharides and galactooligosaccharides.
  • the method for activating good enteric bacteria of the present invention may be performed by ingesting each of the plurality of oligosaccharides so that they can be supplied into the intestine almost simultaneously. It is carried out by taking and ingesting as a composition for activating enteric good bacteria of the present invention comprising a mixture of a plurality of oligosaccharides combined at a blending ratio suitable for activating good enteric bacteria.
  • the intestinal good bacteria activating composition of the present invention comprises the above-mentioned oligosaccharides (particularly selected from the group consisting of lactose, raffinose, lactulose, cellooligosaccharide, xylooligosaccharide, fructooligosaccharide, isomaltoligosaccharide and galactooligosaccharide)
  • oligosaccharides particularly selected from the group consisting of lactose, raffinose, lactulose, cellooligosaccharide, xylooligosaccharide, fructooligosaccharide, isomaltoligosaccharide and galactooligosaccharide
  • the above is contained in a combination ratio suitable for the activation of good enterobacteria (especially bifidobacteria) based on EOS theory.
  • composition for activating the enteric good bacteria is a combination of lactose, raffinose and cellooligosaccharide.
  • An example of a suitable amount of this combination is 28 to 35% by weight of lactose, 48 to 55% by weight of raffinose and 18 to 25% by weight of cellooligosaccharide.
  • Another preferred intestinal good fungus activating composition formulation is a combination of raffinose, lactulose and cellooligosaccharide.
  • An example of a suitable amount of this combination is raffinose 48 to 55% by weight, lactulose 8 to 15% by weight and cellooligosaccharide 38 to 45% by weight.
  • composition for activating the enteric good bacteria are a combination of lactose, raffinose, lactulose and cellooligosaccharide.
  • An example of a suitable blending amount of this combination is 8 to 15% by weight of lactose, 60 to 65% by weight of raffinose, 21 to 25% by weight of lactulose and 3 to 11% by weight of cellooligosaccharide.
  • the plurality of oligosaccharides is a combination of lactose 8, raffinose, lactulose, cellooligosaccharide, xylooligosaccharide, fructooligosaccharide, isomaltoligosaccharide and galactooligosaccharide .
  • lactose 8-12% lactose 8-12%, raffinose 4-6%, lactulose 8-12%, cellooligosaccharide 20-25%, xylooligosaccharide 1-4%, fructooligosaccharide 28 to 32% by weight, isomalt-oligosaccharides 8 to 12% by weight and galactooligosaccharides 8 to 12% by weight.
  • the EOS theory is suitably applied, and an improvement effect is recognized even for the intestinal flora in which the environment varies depending on individual differences, physical condition, age, and the like.
  • the enteric good bacteria active composition of this invention may contain the other additive as needed.
  • the addition amount of other additives is arbitrary as long as the object of the present invention is not impaired.
  • Other additives include, but are not limited to, sugars other than oligosaccharides (such as sucrose), preservatives, colorants, excipients, excipients, hygroscopic agents, and the like.
  • enteric good bacteria (especially bifidobacteria) activation composition of the present invention is not particularly limited, and powders, granules, tablets, capsules, enteric solvents, troches, liquids for internal use, liquids for external use, suspensions, Any form of emulsion, syrup, etc. may be used.
  • the method for producing the enteric good bacteria activating composition of the present invention is not particularly limited, and varies depending on the dosage form, but can be produced and processed by conventional methods conventionally used in various fields.
  • auxiliary agents such as an excipient, a binder, a disintegrant, a lubricant, a corrigent, and a stabilizer may be used depending on the purpose.
  • the intestinal good bacteria activating composition of the present invention can be used as it is, or can be blended in various foods and health functional foods (hereinafter collectively referred to as “foods”).
  • the blending amount is not particularly specified and is arbitrary, and is appropriately determined in consideration of the type and quality of food.
  • blended the enteric good bacteria active composition of this invention contain the component used for foodstuffs, a functional food ingredient, and a food additive within the range which does not impair the effect of this invention. It may be.
  • the intake amount of the composition for activating good enteric bacteria of the present invention varies depending on the state of the intestinal flora, age, weight, symptom, dosage form, etc. In the case of high purity blended powder, it is about 3 to 10 g per day.
  • the oligosaccharides used are as follows. ⁇ Lactose (Replino Foods) ⁇ Raffinose (manufactured by Nippon Beet Sugar Co., Ltd.) ⁇ Lactulose (Morinaga Milk Industry) -Cellooligosaccharide (Nippon Paper Chemicals) ⁇ Xylooligosaccharide (Suntory) ⁇ Fructooligosaccharide (Meiji Food Materia) ⁇ Isomaltooligosaccharide (made by Showa Sangyo Co., Ltd.) ⁇ Galactooligosaccharide (Nisshin Sugar Co., Ltd.) ⁇ Sucrose (manufactured by Nippon Beet Sugar Co., Ltd.)
  • Reference Example 1 Preparation of composition
  • the composition of Reference Example 1 was prepared according to the following procedure.
  • the raffinose component was separated from beet molasses with a chromatographic separator, concentrated, purified and crystallized, and then dried to obtain powdered raffinose.
  • a predetermined amount of sucrose was added to powdered raffinose, mixed well, and granulated to obtain a composition of Reference Example 1 containing 98% by weight raffinose and 2% by weight sucrose.
  • Example 1 (1) Preparation of composition The composition of Example 1 was prepared according to the following procedure. The composition of Example 1 containing 30% by weight of lactose, 50% by weight of raffinose, and 20% by weight of cellooligosaccharide was obtained by thoroughly mixing 600 g of lactose, 1000 g of raffinose and 400 g of cellooligosaccharide until uniform. .
  • Example 2 (1) Preparation of composition
  • the composition of Example 2 was prepared according to the following procedure.
  • a composition of Example 2 containing 50% by weight of raffinose, 10% by weight of lactulose, and 40% by weight of cellooligosaccharide was obtained by thoroughly mixing 1000 g of raffinose, 200 g of lactulose and 800 g of cellooligosaccharide until uniform. .
  • Example 3 (1) Preparation of composition
  • the composition of Example 3 was prepared according to the following procedure. 200 g of lactose, 1240 g of raffinose, 460 g of lactulose and 100 g of cellooligosaccharide are mixed thoroughly until uniform, and then granulated to produce 10 wt% lactose, 62 wt% raffinose, 23 wt% lactulose, 5 wt% cellooligosaccharide The composition of Example 3 was obtained.
  • Example 4 (1) Preparation of composition The composition of Example 4 was prepared according to the following procedure. 100 g of lactose, 49 g of raffinose, 100 g of lactulose, 230 g of cellooligosaccharide, 20 g of xylooligosaccharide, 300 g of fructooligosaccharide, 100 g of isomaltoligosaccharide, 100 g of galactooligosaccharide and 1 g of sucrose are mixed well until granulated, and granulated.
  • Example 4 Wt%, raffinose 4.9 wt%, lactulose 10 wt%, cellooligosaccharide 23 wt%, xylooligosaccharide 2 wt%, fructooligosaccharide 30 wt%, isomaltoligosaccharide 10 wt%, galactooligosaccharide 10 wt%, sucrose 0.
  • the composition of Example 4 containing 1% by weight was obtained.
  • (2) Evaluation The composition of Example 4 was ingested by 5 persons (3 males and 2 females) with constipation for 5 g / day a week. Carried out. As a result, 4 out of 5 responded that the number of stools was improved compared to when they were not ingested. Two people in particular also showed changes in the amount of increase.
  • the present invention it is possible to obtain an improvement effect on the intestinal bacterial flora whose environment varies depending on individual differences, physical condition, age, and the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Provided is a method for activating a good intestinal bacterium for the purpose of improving an intestinal bacterial flora. A method for activating a good intestinal bacterium, comprising selecting multiple oligosaccharides that are suitable for the activation of a good intestinal bacterium of interest, combining the multiple oligosaccharides at a content ratio suitable for the activation of the good intestinal bacterium, and administering the resultant combination to an intestinal bacterial flora. The method for activating a good intestinal bacterium can achieve an improving effect on an intestinal bacterial flora for which the environment is varied among individuals, physical conditions, ages and the like.

Description

腸内善玉菌の活性化方法及び腸内善玉菌活性化組成物Method for activating good enterobacteria and enteric good bacteria activation composition
　本発明は、腸内善玉菌の活性化する方法及び腸内善玉菌の活性化することにより腸内細菌叢を改善する方法及び腸内善玉菌活性化組成物に関する。 The present invention relates to a method for activating good enterobacteria, a method for improving intestinal flora by activating good enterobacteria, and an enteric good bacteria activating composition.
　人間の腸内に常在する腸内細菌は、人間の健康と重要な係わりを有する。例えば、腸内細菌の善玉菌の代表であるビフィズス菌は、下痢や便秘等の予防、治療効果や腸内の有害細菌の増殖抑制作用等の整腸作用を有することが知られている。 腸 Intestinal bacteria that are permanently present in the human intestine have an important relationship with human health. For example, Bifidobacteria, which is a representative of enterobacterium good bacteria, is known to have an intestinal action such as prevention and treatment of diarrhea and constipation, and an effect of inhibiting the growth of harmful bacteria in the intestine.
　腸内細菌叢における各種腸内細菌叢の割合は、個人個人で異なり、さらには年齢、栄養成分、ストレス等の要因により変動する。特にビフィズス菌は疾患や加齢により減少する傾向にあるため、腸内細菌叢におけるビフィズス菌等の善玉菌の割合を増加させる試みがなされている。従来から乳製品にビフィズス菌を添加させた食品等でビフィズス菌を摂取する方法がある。しかしながら、経口的にビフィズス菌を摂取した場合、腸内まで生存したビフィズス菌が供給されにくく、必ずしも実際に所望の整腸効果を十分に得ることができないことが多い。 The proportion of various intestinal flora in the intestinal flora varies from individual to individual, and also varies depending on factors such as age, nutritional components, and stress. In particular, since bifidobacteria tend to decrease due to disease and aging, attempts have been made to increase the proportion of good bacteria such as bifidobacteria in the intestinal flora. Conventionally, there is a method of ingesting bifidobacteria in foods obtained by adding bifidobacteria to dairy products. However, when bifidobacteria are ingested orally, it is difficult to supply the bifidobacteria that have survived to the intestines, and the desired intestinal regulation effect cannot always be sufficiently obtained in many cases.
　一方で、ラクチュロース、メリビオース、ラフィノース、スタキオース、イソマルトオリゴ糖、ガラクトオリゴ糖、またはフラクトオリゴ糖等のオリゴ糖には、ビフィズス菌を増加させる効果があることが知られており、オリゴ糖を配合した食品、医薬品等などが開発されている。
　例えば、特許文献１には、オリゴ糖を配合したパンが開示されている。また、特許文献２には、ラフィノースを配合した飼料が開示されている。 On the other hand, it is known that oligosaccharides such as lactulose, melibiose, raffinose, stachyose, isomalto-oligosaccharide, galacto-oligosaccharide, or fructooligosaccharide have an effect of increasing bifidobacteria, Drugs are being developed.
For example, Patent Document 1 discloses a bread containing an oligosaccharide. Patent Document 2 discloses a feed containing raffinose.
　これらのオリゴ糖には、ヒトの消化酵素で分解されないこと、腸管から吸収されないこと、ビフィズス菌に選択的に資化されること等の共通した性質を有する。
　しかしながら、これらのオリゴ糖は、必ずしもビフィズス菌等の善玉菌のみに選択的に利用されるものではなく、オリゴ糖を利用して増殖する悪玉菌が存在する。
　上記オリゴ糖をそれぞれ単独で食品などに添加して経口摂取する場合、各々のオリゴ糖の特長を発揮するにとどまっていた。また、どのオリゴ糖が整腸効果を発現するかについては個人差があり、適さないオリゴ糖を摂取すると下痢等の副作用を引き起こす場合があった。 These oligosaccharides have common properties such as being not degraded by human digestive enzymes, not being absorbed from the intestinal tract, and being selectively assimilated by bifidobacteria.
However, these oligosaccharides are not necessarily selectively used only for good bacteria such as bifidobacteria, and there are bad bacteria that proliferate using oligosaccharides.
When each of the above oligosaccharides is added to food or the like and taken orally, the oligosaccharides have only exhibited their characteristics. In addition, there are individual differences in which oligosaccharides exert the intestinal regulating effect, and ingestion of unsuitable oligosaccharides may cause side effects such as diarrhea.
特開平７－５０９７６号公報Japanese Patent Application Laid-Open No. 7-50976 特開平５－３７５８号公報JP-A-5-3758
　このように、オリゴ糖はその種類によって、善玉菌、悪玉菌に資化される程度には大きな差があり、必ずしも満足な腸内細菌叢の改善効果が得られない場合があった。このように個人差のある腸内細菌叢を改善し、効果の高い整腸作用を得る方法が確立されていないのが実状である。 As described above, oligosaccharides vary greatly in the degree of utilization by good bacteria and bad bacteria depending on the type thereof, and a satisfactory improvement effect on intestinal bacterial flora may not always be obtained. Thus, the actual situation is that a method for improving the intestinal microflora having individual differences and obtaining a highly effective intestinal regulating action has not been established.
　かかる状況下、本発明の目的は、腸内細菌叢を改善するための腸内善玉菌の活性化方法及び腸内善玉菌活性化組成物を提供することにある。 Under such circumstances, an object of the present invention is to provide a method for activating good enterobacteria and a composition for activating good enterobacteria to improve the intestinal flora.
　本発明者は、上記課題を解決すべく鋭意研究を重ねた結果、複数のオリゴ糖を混合して摂取することで腸内善玉菌の活性化に対しての相乗効果が得られることを見出し、本発明に至った。 As a result of intensive research to solve the above problems, the present inventors have found that a synergistic effect on the activation of good enterobacteriaceae can be obtained by ingesting a mixture of a plurality of oligosaccharides, The present invention has been reached.
　すなわち、本発明は、以下の発明に係るものである。
　＜１＞　対象となる腸内善玉菌の活性化に適する複数のオリゴ糖を選定し、該複数のオリゴ糖を前記腸内善玉菌の活性化に適する配合割合で組み合わせて腸内細菌叢に与える腸内善玉菌の活性化方法。
　＜２＞　前記複数のオリゴ糖が、ラクトース、ラフィノース、ラクチュロース、セロオリゴ糖、キシロオリゴ糖、フラクトオリゴ糖、イソマルトオリゴ糖及びガラクトオリゴ糖からなる群から選択される２種以上である前記＜１＞記載の腸内善玉菌の活性化方法。
　＜３＞　前記複数のオリゴ糖が、ラクトース、ラフィノース及びセロオリゴ糖の組み合わせである前記＜１＞記載の腸内善玉菌の活性化方法。
　＜４＞　前記複数のオリゴ糖が、ラフィノース、ラクチュロース及びセロオリゴ糖の組み合わせである前記＜１＞記載の腸内善玉菌の活性化方法。
　＜５＞　前記複数のオリゴ糖が、ラクトース、ラフィノース、ラクチュロース及びセロオリゴ糖の組み合わせである前記＜１＞記載の腸内善玉菌の活性化方法。
　＜６＞　前記複数のオリゴ糖が、ラクトース、ラフィノース、ラクチュロース、セロオリゴ糖、キシロオリゴ糖、フラクトオリゴ糖、イソマルトオリゴ糖及びガラクトオリゴ糖である前記＜１＞記載の腸内善玉菌の活性化方法。
　＜７＞　対象となる腸内善玉菌の活性化に適する複数のオリゴ糖を選定し、該複数のオリゴ糖を前記腸内善玉菌の活性化に適する配合割合で組み合わせた混合物を含有する腸内善玉菌活性化組成物。
　＜８＞　前記複数のオリゴ糖が、ラクトース、ラフィノース、ラクチュロース、セロオリゴ糖、キシロオリゴ糖、フラクトオリゴ糖、イソマルトオリゴ糖及びガラクトオリゴ糖からなる群から選択される２種以上である前記＜７＞記載の腸内善玉菌活性化組成物。
　＜９＞　前記複数のオリゴ糖が、ラクトース、ラフィノース及びセロオリゴ糖の組み合わせである前記＜７＞記載の腸内善玉菌活性化組成物。
　＜１０＞　前記複数のオリゴ糖が、ラフィノース、ラクチュロース及びセロオリゴ糖の組み合わせである前記＜７＞記載の腸内善玉菌活性化組成物。
　＜１１＞　前記複数のオリゴ糖が、ラクトース、ラフィノース、ラクチュロース及びセロオリゴ糖の組み合わせである前記＜７＞記載の腸内善玉菌活性化組成物。
　＜１２＞　前記複数のオリゴ糖が、ラクトース、ラフィノース、ラクチュロース、セロオリゴ糖、キシロオリゴ糖、フラクトオリゴ糖、イソマルトオリゴ糖及びガラクトオリゴ糖である前記＜７＞記載の腸内善玉菌活性化組成物。 That is, the present invention relates to the following inventions.
<1> Select a plurality of oligosaccharides suitable for the activation of the beneficial enteric bacteria, and combine the plurality of oligosaccharides at a blending ratio suitable for the activation of the enteric good bacteria to give to the intestinal flora A method for activating good intestinal bacteria.
<2> The intestine according to <1>, wherein the plurality of oligosaccharides are two or more selected from the group consisting of lactose, raffinose, lactulose, cellooligosaccharide, xylooligosaccharide, fructooligosaccharide, isomaltooligosaccharide, and galactooligosaccharide. How to activate Uchizen good bacteria.
<3> The method for activating good enterobacteria according to <1>, wherein the plurality of oligosaccharides is a combination of lactose, raffinose and cellooligosaccharide.
<4> The method for activating good enterobacteria according to <1>, wherein the plurality of oligosaccharides is a combination of raffinose, lactulose and cellooligosaccharide.
<5> The method for activating good enterobacteria according to <1>, wherein the plurality of oligosaccharides is a combination of lactose, raffinose, lactulose and cellooligosaccharide.
<6> The method for activating good enteric bacteria according to <1>, wherein the plurality of oligosaccharides are lactose, raffinose, lactulose, cellooligosaccharide, xylooligosaccharide, fructooligosaccharide, isomaltoligosaccharide, and galactooligosaccharide.
<7> An intestine containing a mixture of a plurality of oligosaccharides suitable for activating good enteric bacteria in a target, and a combination of the plurality of oligosaccharides combined in a proportion suitable for activating the enteric good bacteria A good bacteria activation composition.
<8> The intestine according to <7>, wherein the plurality of oligosaccharides are two or more selected from the group consisting of lactose, raffinose, lactulose, cellooligosaccharide, xylooligosaccharide, fructooligosaccharide, isomaltooligosaccharide, and galactooligosaccharide. Uchizen good bacteria activation composition.
<9> The enteric good bacteria activating composition according to <7>, wherein the plurality of oligosaccharides is a combination of lactose, raffinose and cellooligosaccharide.
<10> The enteric good bacteria activating composition according to <7>, wherein the plurality of oligosaccharides is a combination of raffinose, lactulose, and cellooligosaccharide.
<11> The enteric good bacteria activating composition according to <7>, wherein the plurality of oligosaccharides is a combination of lactose, raffinose, lactulose, and cellooligosaccharide.
<12> The enteric good bacteria activating composition according to <7>, wherein the plurality of oligosaccharides are lactose, raffinose, lactulose, cellooligosaccharide, xylooligosaccharide, fructooligosaccharide, isomaltoligosaccharide, and galactooligosaccharide.
　本発明によれば、個人差、体調、年齢などで環境が異なる腸内細菌叢に対しても、改善効果を得られる腸内善玉菌の活性化方法及び腸内善玉菌活性化組成物が提供される。 ADVANTAGE OF THE INVENTION According to this invention, the activation method of the enterobacterium good bacteria which can obtain the improvement effect with respect to the intestinal microflora from which environment differs according to individual differences, physical condition, age, etc., and an enterobacterium good bacteria activation composition Is done.
　まず、本発明の腸内善玉菌の活性化方法は、腸内善玉菌の活性化に適する複数のオリゴ糖を選定し、該複数のオリゴ糖を前記腸内善玉菌の活性化に適する配合割合で組み合わせて腸内細菌叢に与えることを特徴とする。
　また、本発明の腸内善玉菌活性化組成物は、上記腸内善玉菌の活性化方法を利用し、対象となる腸内善玉菌の活性化に適する複数のオリゴ糖を選定し、該複数のオリゴ糖を前記腸内善玉菌の活性化に適する配合割合で組み合わせた混合物を含有することを特徴とする。
　なお、「腸内善玉菌」とは、人の消化管内における有用微生物であり、具体的には、ビフィズス菌、乳酸菌等が挙げられるが、本発明の腸内善玉菌の活性化方法は特にビフィズス菌の活性化に適する。 First, the method for activating good enteric bacteria of the present invention selects a plurality of oligosaccharides suitable for the activation of good enteric bacteria, and the blending ratio of the plurality of oligosaccharides suitable for the activation of the good enteric bacteria It is characterized by being given to the intestinal flora in combination.
Further, the composition for activating good enteric bacteria of the present invention uses the above-mentioned method for activating good enteric bacteria, selects a plurality of oligosaccharides suitable for activating the target enteric good bacteria, It is characterized by containing the mixture which combined these oligosaccharides with the mixture ratio suitable for activation of the said enteric good bacteria.
The “intestinal good bacteria” are useful microorganisms in the human digestive tract, and specific examples include bifidobacteria and lactic acid bacteria. The method for activating enteric good bacteria in the present invention is particularly bifidos. Suitable for activating bacteria.
　上記腸内善玉菌の活性化方法は、本発明者が開発した独自理論ＥＯＳ理論に基づくものである。ＥＯＳ理論とはEnterobacteria Oligosaccharide Synergy（腸内細菌－オリゴ糖　相乗効果）を利用したものであり、より具体的には腸内菌叢の有用菌代表格のビフィズス菌種類にビフィズス菌増殖因子である最適なオリゴ糖を選定し、それを混合することで、相乗効果を生み出し、ビフィズス菌全体の増殖効果を最大限に高める理論である。
　ＥＯＳ理論に基づく活性化方法により、オリゴ糖が相互補完し合うことで、腸内に棲息するビフィズス菌をムダなく利用することで、オリゴ糖を単体として使用するより効果がある。また、対象となるビフィズス菌が活性化することにより、他の腸内善玉菌（他のビフィズス菌や乳酸菌など）を含む腸内細菌叢が改善されるものと推測される。 The method for activating the enteric good bacteria is based on the original theory EOS theory developed by the present inventors. The EOS theory uses Enterobacteria Oligosaccharide Synergy, and more specifically, it is the optimal bifidobacterial growth factor for the type of bifidobacteria that is representative of useful bacteria in the intestinal flora. This is a theory that creates a synergistic effect by selecting and mixing various oligosaccharides and maximizing the growth effect of the entire bifidobacteria.
By the activation method based on the EOS theory, the oligosaccharides complement each other, and the bifidobacteria inhabiting the intestine are used without waste, which is more effective than using the oligosaccharide alone. In addition, when the target bifidobacteria are activated, it is presumed that the intestinal bacterial flora including other enteric good bacteria (such as other bifidobacteria and lactic acid bacteria) is improved.
　なお、この効果は、人間の腸内において、グルコースやショ糖などの本発明の対象となるオリゴ糖を含まない糖類の組み合わせでは認められず、ＥＯＳ理論に基づく、複数のオリゴ糖の組み合わせ特有の効果である。
　そのため、ＥＯＳ理論による腸内善玉菌の活性化方法に基づいて、複数のオリゴ糖を服用または摂取することは、副作用の恐れがほとんどなく、安心して日常的に使用できる点で非常に有効である。 In addition, this effect is not recognized in the human intestine in the combination of saccharides that do not include the oligosaccharide that is the subject of the present invention, such as glucose and sucrose, and is unique to the combination of a plurality of oligosaccharides based on the EOS theory. It is an effect.
Therefore, taking or ingesting multiple oligosaccharides based on the method of activating good enterobacterium in EOS theory is very effective in that it can be used safely and with little risk of side effects. .
　本発明において使用することができるオリゴ糖は特に制限はなく、例えば、ラクトース、ラフィノース、ラクチュロース、メリビオース、スタキオース、セロビオース、セロオリゴ糖、イソマルトオリゴ糖、ガラクトオリゴ糖、フラクトオリゴ糖、キシロオリゴ糖、大豆オリゴ糖等を挙げることができる。
　上記オリゴ糖は、市販品を使用したり、オリゴ糖を含む天然物の抽出物から分離、精製された精製品を使用したりすることができる。
　これらのオリゴ糖の形態は、粉状、液状、シロップ状などいずれの形態であってもよいが、取り扱いの観点からは、通常、粉状やシロップ状である。 The oligosaccharide that can be used in the present invention is not particularly limited. For example, lactose, raffinose, lactulose, melibiose, stachyose, cellobiose, cellooligosaccharide, isomaltoligosaccharide, galactooligosaccharide, fructooligosaccharide, xylooligosaccharide, soybean oligosaccharide, etc. Can be mentioned.
As the oligosaccharide, a commercially available product can be used, or a purified product separated and purified from an extract of a natural product containing the oligosaccharide can be used.
These oligosaccharides may be in any form such as powder, liquid or syrup, but are usually powder or syrup from the viewpoint of handling.
　上記オリゴ糖の中でも、腸内細菌叢を改善する効果が特に認められることから、ラクトース、ラフィノース、ラクチュロース、セロオリゴ糖、キシロオリゴ糖、フラクトオリゴ糖、イソマルトオリゴ糖及びガラクトオリゴ糖からなる群から選択される２種以上を使用することが好ましい。
　これらのオリゴ糖は、人の消化管内では消化、吸収されずに腸内に到達し、腸内善玉菌（ビフィズス菌、乳酸菌等）を増殖させる効果が高い。 Among the above oligosaccharides, since the effect of improving the intestinal microflora is particularly recognized, 2 selected from the group consisting of lactose, raffinose, lactulose, cellooligosaccharide, xylooligosaccharide, fructooligosaccharide, isomaltoligosaccharide and galactooligosaccharide 2 It is preferable to use more than one species.
These oligosaccharides reach the intestine without being digested and absorbed in the human digestive tract, and are highly effective in proliferating good intestinal bacteria (bifidobacteria, lactic acid bacteria, etc.).
　オリゴ糖の選定、配合割合は、上記ＥＯＳ理論に基づいて決定される。
　オリゴ糖の中でもラフィノースは、対象者に整腸作用を与える割合が高いことから、ラフィノースを含むことが好ましく、ラフィノースを資化する能力を有さない、あるいはラフィノースを資化する能力が弱い腸内善玉菌を活性化するために、他のオリゴ糖を組み合わせることが好ましい。また、コストの観点からは、乳糖の配合を高めることが好ましい。
　ラフィノースをベースとする場合の配合例の挙げると、全量を１００重量％として場合に、ラフィノースが１重量％～８０重量％（好ましくは３～６０重量％）、他のオリゴ糖が７０重量％～９９重量％（好ましくは４０～９７重量％）である。 The selection and blending ratio of oligosaccharides are determined based on the EOS theory.
Among the oligosaccharides, raffinose has a high ratio of giving an intestinal regulating action to a subject. Therefore, it is preferable to include raffinose, and it has no ability to assimilate raffinose or has a weak ability to assimilate raffinose. In order to activate good bacteria, it is preferable to combine other oligosaccharides. From the viewpoint of cost, it is preferable to increase the lactose content.
In the case of raffinose as a base, when the total amount is 100 wt%, raffinose is 1 wt% to 80 wt% (preferably 3 to 60 wt%), and other oligosaccharides are 70 wt% to 99% by weight (preferably 40 to 97% by weight).
　ＥＯＳ理論が適用できる好適なオリゴ糖の組み合わせは、ラクトース、ラフィノース及びセロオリゴ糖の組み合わせである。 A suitable combination of oligosaccharides to which the EOS theory can be applied is a combination of lactose, raffinose and cellooligosaccharide.
　ＥＯＳ理論が適用できる他の好適なオリゴ糖の組み合わせは、ラフィノース、ラクチュロース及びセロオリゴ糖の組み合わせである。 Other suitable oligosaccharide combinations to which the EOS theory can be applied are raffinose, lactulose and cellooligosaccharide combinations.
　ＥＯＳ理論が適用できる他の好適なオリゴ糖の組み合わせは、ラクトース、ラフィノース、ラクチュロース及びセロオリゴ糖の組み合わせである。 Other suitable oligosaccharide combinations to which the EOS theory can be applied are combinations of lactose, raffinose, lactulose and cellooligosaccharide.
　ＥＯＳ理論が適用できる他の好適なオリゴ糖の組み合わせは、ラクトース、ラフィノース、ラクチュロース、セロオリゴ糖、キシロオリゴ糖、フラクトオリゴ糖、イソマルトオリゴ糖及びガラクトオリゴ糖の組み合わせである。 Other suitable oligosaccharide combinations to which the EOS theory can be applied are combinations of lactose, raffinose, lactulose, cellooligosaccharides, xylooligosaccharides, fructooligosaccharides, isomaltoligosaccharides and galactooligosaccharides.
　本発明の腸内善玉菌の活性化方法は、上記複数のオリゴ糖のそれぞれをほぼ同時に腸内に供給できるように摂取することによって行われてもよいが、通常は、複数のオリゴ糖を該複数のオリゴ糖を前記腸内善玉菌の活性化に適する配合割合で組み合わせた混合物を含む本発明の腸内善玉菌活性化組成物として服用、摂取されることで行われる。 The method for activating good enteric bacteria of the present invention may be performed by ingesting each of the plurality of oligosaccharides so that they can be supplied into the intestine almost simultaneously. It is carried out by taking and ingesting as a composition for activating enteric good bacteria of the present invention comprising a mixture of a plurality of oligosaccharides combined at a blending ratio suitable for activating good enteric bacteria.
　本発明の腸内善玉菌活性化組成物は、上記のオリゴ糖（特にはラクトース、ラフィノース、ラクチュロース、セロオリゴ糖、キシロオリゴ糖、フラクトオリゴ糖、イソマルトオリゴ糖及びガラクトオリゴ糖からなる群から選択される２種以上）をＥＯＳ理論に基づく腸内善玉菌（特にビフィズス菌）の活性化に適する配合割合で組み合わせた混合物を含有する。 The intestinal good bacteria activating composition of the present invention comprises the above-mentioned oligosaccharides (particularly selected from the group consisting of lactose, raffinose, lactulose, cellooligosaccharide, xylooligosaccharide, fructooligosaccharide, isomaltoligosaccharide and galactooligosaccharide) The above is contained in a combination ratio suitable for the activation of good enterobacteria (especially bifidobacteria) based on EOS theory.
　好適な腸内善玉菌活性化組成物の配合例は、ラクトース、ラフィノース及びセロオリゴ糖の組み合わせである。この組み合わせの好適な配合量の一例は、ラクトース２８～３５重量％、ラフィノース４８～５５重量％及びセロオリゴ糖１８～２５重量％である。 A preferred example of the composition for activating the enteric good bacteria is a combination of lactose, raffinose and cellooligosaccharide. An example of a suitable amount of this combination is 28 to 35% by weight of lactose, 48 to 55% by weight of raffinose and 18 to 25% by weight of cellooligosaccharide.
　他の好適な腸内善玉菌活性化組成物の配合例は、ラフィノース、ラクチュロース及びセロオリゴ糖の組み合わせである。この組み合わせの好適な配合量の一例は、ラフィノース４８～５５重量％、ラクチュロース８～１５重量％及びセロオリゴ糖３８～４５重量％である。 Another preferred intestinal good fungus activating composition formulation is a combination of raffinose, lactulose and cellooligosaccharide. An example of a suitable amount of this combination is raffinose 48 to 55% by weight, lactulose 8 to 15% by weight and cellooligosaccharide 38 to 45% by weight.
　他の好適な腸内善玉菌活性化組成物の配合例は、ラクトース、ラフィノース、ラクチュロース及びセロオリゴ糖の組み合わせである。この組み合わせの好適な配合量の一例は、ラクトース８～１５重量％、ラフィノース６０～６５重量％、ラクチュロース２１～２５重量％及びセロオリゴ糖３～１１重量％である。 Other preferred examples of the composition for activating the enteric good bacteria are a combination of lactose, raffinose, lactulose and cellooligosaccharide. An example of a suitable blending amount of this combination is 8 to 15% by weight of lactose, 60 to 65% by weight of raffinose, 21 to 25% by weight of lactulose and 3 to 11% by weight of cellooligosaccharide.
　他の好適な腸内善玉菌活性化組成物の配合例は、前記複数のオリゴ糖が、ラクトース８、ラフィノース、ラクチュロース、セロオリゴ糖、キシロオリゴ糖、フラクトオリゴ糖、イソマルトオリゴ糖及びガラクトオリゴ糖の組み合わせである。この組み合わせの好適な配合量の一例は、ラクトース８～１２重量％、ラフィノース４～６重量％、ラクチュロース８～１２重量％、セロオリゴ糖２０～２５重量％、キシロオリゴ糖１～４重量％、フラクトオリゴ糖２８～３２重量％、イソマルトオリゴ糖８～１２重量％及びガラクトオリゴ糖８～１２重量％である。 In another preferred intestinal good fungus activating composition formulation, the plurality of oligosaccharides is a combination of lactose 8, raffinose, lactulose, cellooligosaccharide, xylooligosaccharide, fructooligosaccharide, isomaltoligosaccharide and galactooligosaccharide . Examples of suitable amounts of this combination are: lactose 8-12%, raffinose 4-6%, lactulose 8-12%, cellooligosaccharide 20-25%, xylooligosaccharide 1-4%, fructooligosaccharide 28 to 32% by weight, isomalt-oligosaccharides 8 to 12% by weight and galactooligosaccharides 8 to 12% by weight.
　このような配合割合でオリゴ糖を組み合わせによるとＥＯＳ理論が好適に適用されて個人差、体調、年齢などで環境が異なる腸内細菌叢に対しても、改善効果が認められる。 When the oligosaccharide is combined at such a blending ratio, the EOS theory is suitably applied, and an improvement effect is recognized even for the intestinal flora in which the environment varies depending on individual differences, physical condition, age, and the like.
　なお、本発明の腸内善玉菌活性化組成物は、必要に応じて他の添加剤を含有していてもよい。他の添加剤の添加量は、本発明の目的を損なわない範囲において任意である。
　他の添加剤としては、オリゴ糖以外の糖類（ショ糖等）、保存料、着色料、賦形剤、賦形剤、吸湿剤等が挙げられるがこれらに限定されない。 In addition, the enteric good bacteria active composition of this invention may contain the other additive as needed. The addition amount of other additives is arbitrary as long as the object of the present invention is not impaired.
Other additives include, but are not limited to, sugars other than oligosaccharides (such as sucrose), preservatives, colorants, excipients, excipients, hygroscopic agents, and the like.
　本発明の腸内善玉菌（特にビフィズス菌）活性化組成物の形態は特に制限はなく、散剤、顆粒剤、錠剤、カプセル剤、腸溶剤、トローチ、内用液剤、外用液剤、懸濁剤、乳剤、シロップ剤、等のいかなる形態でもよい。 The form of the enteric good bacteria (especially bifidobacteria) activation composition of the present invention is not particularly limited, and powders, granules, tablets, capsules, enteric solvents, troches, liquids for internal use, liquids for external use, suspensions, Any form of emulsion, syrup, etc. may be used.
　本発明の腸内善玉菌活性化組成物の製造方法は特に制限はなく、剤形により異なるが、各分野において従来公知に用いられている常法により製造、加工可能である。製剤に当たっては、目的に応じてさらに賦形剤、結合剤、崩壊剤、潤沢剤、矯味剤、安定化剤などの補助剤を用いてもよい。 The method for producing the enteric good bacteria activating composition of the present invention is not particularly limited, and varies depending on the dosage form, but can be produced and processed by conventional methods conventionally used in various fields. In the preparation, auxiliary agents such as an excipient, a binder, a disintegrant, a lubricant, a corrigent, and a stabilizer may be used depending on the purpose.
　本発明の腸内善玉菌活性化組成物は、そのまま利用することもできるし、各種食品、保健機能食品（以下、「食品等」と総称する。）に配合することができる。配合量としては特に規定するものではなく任意であり、食品等の種類、品質等を考慮して適宜決定される。 The intestinal good bacteria activating composition of the present invention can be used as it is, or can be blended in various foods and health functional foods (hereinafter collectively referred to as “foods”). The blending amount is not particularly specified and is arbitrary, and is appropriately determined in consideration of the type and quality of food.
　なお、本発明の腸内善玉菌活性化組成物を配合した食品等は、本発明の効果を損なわない範囲内で、食品等に使用される成分、機能性食品成分や食品添加剤を含有していてもよい。 In addition, the food etc. which mix | blended the enteric good bacteria active composition of this invention contain the component used for foodstuffs, a functional food ingredient, and a food additive within the range which does not impair the effect of this invention. It may be.
　本発明の腸内善玉菌活性化組成物の摂取量は、腸内細菌叢の状態、年齢、体重、症状、剤形等により異なるが、成人に対して通常はオリゴ糖合計量として、オリゴ糖分高純度配合粉末の場合、一日当り３ｇ～１０ｇ程度である。 The intake amount of the composition for activating good enteric bacteria of the present invention varies depending on the state of the intestinal flora, age, weight, symptom, dosage form, etc. In the case of high purity blended powder, it is about 3 to 10 g per day.
　以下、実施例により本発明を更に詳細に説明するが、本発明は、その要旨を変更しない限り以下の実施例に限定されるものではない。 Hereinafter, the present invention will be described in more detail with reference to examples. However, the present invention is not limited to the following examples unless the gist thereof is changed.
　使用したオリゴ糖は次の通りである。
・ラクトース（レプリノフーズ社製）
・ラフィノース（日本甜菜精糖社製）
・ラクチュロース（森永乳業社製）
・セロオリゴ糖（日本製紙ケミカル社製）
・キシロオリゴ糖（サントリー社製）
・フラクトオリゴ糖（明治フードマテリア社製）
・イソマルトオリゴ糖（昭和産業社製）
・ガラクトオリゴ糖（日新製糖社製）
・ショ糖（日本甜菜精糖社製） The oligosaccharides used are as follows.
・ Lactose (Replino Foods)
・ Raffinose (manufactured by Nippon Beet Sugar Co., Ltd.)
・ Lactulose (Morinaga Milk Industry)
-Cellooligosaccharide (Nippon Paper Chemicals)
・ Xylooligosaccharide (Suntory)
・ Fructooligosaccharide (Meiji Food Materia)
・ Isomaltooligosaccharide (made by Showa Sangyo Co., Ltd.)
・ Galactooligosaccharide (Nisshin Sugar Co., Ltd.)
・ Sucrose (manufactured by Nippon Beet Sugar Co., Ltd.)
（参考例１）
（１）組成物の調整
　以下の手順により参考例１の組成物を調整した。
　ビート糖蜜からラフィノース成分をクロマト分離装置で分離、濃縮、精製結晶化した後に、乾燥することで、粉末状のラフィノースを得た。粉末状のラフィノースに所定量のショ糖を添加して十分に混合し、造粒することにより、ラフィノース９８重量％、ショ糖２重量％を含む参考例１の組成物を得た。 (Reference Example 1)
(1) Preparation of composition The composition of Reference Example 1 was prepared according to the following procedure.
The raffinose component was separated from beet molasses with a chromatographic separator, concentrated, purified and crystallized, and then dried to obtain powdered raffinose. A predetermined amount of sucrose was added to powdered raffinose, mixed well, and granulated to obtain a composition of Reference Example 1 containing 98% by weight raffinose and 2% by weight sucrose.
（２）モニターの選出
　便秘気味の１５６人に参考例１の組成物を１日５～１０ｇで３０日間程度摂取してもらい、参考例１の組成物で整腸効果が認められない人間を以下の実施例のモニターとした。 (2) Selection of monitors 156 people who are constipated take the composition of Reference Example 1 at 5-10 g per day for about 30 days. It was set as the monitor of the Example.
　モニターに対して、ＥＯＳ理論に基づき調査を行ったところ、以下の実施例１～３の配合割合の組成物が腸内善玉菌の活性化に寄与すると判断した。 When the monitor was investigated based on the EOS theory, it was determined that the composition of the blending ratios of Examples 1 to 3 below contributed to the activation of good enteric bacteria.
（実施例１）
（１）組成物の調整
　以下の手順により実施例１の組成物を調整した。
　ラクトース６００ｇ、ラフィノース１０００ｇ及びセロオリゴ糖４００ｇを均一になるまで十分に混合した後に造粒することでラクトース３０重量％、ラフィノース５０重量％、セロオリゴ糖２０重量％を含む実施例１の組成物を得た。 Example 1
(1) Preparation of composition The composition of Example 1 was prepared according to the following procedure.
The composition of Example 1 containing 30% by weight of lactose, 50% by weight of raffinose, and 20% by weight of cellooligosaccharide was obtained by thoroughly mixing 600 g of lactose, 1000 g of raffinose and 400 g of cellooligosaccharide until uniform. .
（２）評価
　ＥＯＳ理論にて実施例１の組成物が効果があると認定されたモニター１６人に、実施例１の組成物を、１日５～１０ｇで７日間摂取してもらい、参考例１の組成物との整腸効果の違いをアンケートした。
　その結果、１６人中、１１人が実施例１の組成物の方が効果があると回答した。 (2) Evaluation 16 people who were recognized by the EOS theory that the composition of Example 1 was effective were ingested the composition of Example 1 at 5-10 g per day for 7 days, and a reference example. The difference in intestinal effect from the composition of 1 was surveyed.
As a result, 11 out of 16 responded that the composition of Example 1 was more effective.
（実施例２）
（１）組成物の調整
　以下の手順により実施例２の組成物を調整した。
　ラフィノース１０００ｇ、ラクチュロース２００ｇ及びセロオリゴ糖８００ｇを均一になるまで十分に混合した後に造粒することでラフィノース５０重量％、ラクチュロース１０重量％、セロオリゴ糖４０重量％を含む実施例２の組成物を得た。 (Example 2)
(1) Preparation of composition The composition of Example 2 was prepared according to the following procedure.
A composition of Example 2 containing 50% by weight of raffinose, 10% by weight of lactulose, and 40% by weight of cellooligosaccharide was obtained by thoroughly mixing 1000 g of raffinose, 200 g of lactulose and 800 g of cellooligosaccharide until uniform. .
（２）評価
　ＥＯＳ理論にて実施例２の組成物が効果があると認定されたモニター１９人に、実施例１の組成物を、１日５～１０ｇで７日間摂取してもらい、参考例１の組成物との整腸効果の違いをアンケートした。
　その結果、１９人中、１６人が実施例２の組成物の方が効果があると回答した。 (2) Evaluation 19 people who were confirmed by EOS theory that the composition of Example 2 was effective were ingested the composition of Example 1 at 5-10 g per day for 7 days. The difference in intestinal effect from the composition of 1 was surveyed.
As a result, 16 out of 19 responded that the composition of Example 2 was more effective.
（実施例３）
（１）組成物の調整
　以下の手順により実施例３の組成物を調整した。
　ラクトース２００ｇ、ラフィノース１２４０ｇ、ラクチュロース４６０ｇ及びセロオリゴ糖１００ｇを均一になるまで十分に混合した後に造粒することでラクトース１０重量％、ラフィノース６２重量％、ラクチュロース２３重量％、セロオリゴ糖５重量％を含む実施例３の組成物を得た。 (Example 3)
(1) Preparation of composition The composition of Example 3 was prepared according to the following procedure.
200 g of lactose, 1240 g of raffinose, 460 g of lactulose and 100 g of cellooligosaccharide are mixed thoroughly until uniform, and then granulated to produce 10 wt% lactose, 62 wt% raffinose, 23 wt% lactulose, 5 wt% cellooligosaccharide The composition of Example 3 was obtained.
（２）評価
　ＥＯＳ理論にて実施例３の組成物が効果があると認定されたモニター１２２人に、実施例１の組成物を、１日３～１０ｇで１４日間摂取してもらい、参考例１の組成物との整腸効果の違いをアンケートした。
　その結果、１２２人中、７８人が実施例３の組成物の方が効果があると回答した。 (2) Evaluation 122 people who were recognized by the EOS theory that the composition of Example 3 was effective had the composition of Example 1 ingested for 3 days at 3-10 g for 14 days. The difference in intestinal effect from the composition of 1 was surveyed.
As a result, 78 out of 122 responded that the composition of Example 3 was more effective.
（実施例４）
（１）組成物の調整
　以下の手順により実施例４の組成物を調整した。
　ラクトース１００ｇ、ラフィノース４９ｇ、ラクチュロース１００ｇ、セロオリゴ糖２３０ｇ、キシロオリゴ糖２０ｇ、フラクトオリゴ糖３００ｇ、イソマルトオリゴ糖１００ｇ、ガラクトオリゴ糖１００ｇ、ショ糖１ｇを均一になるまで十分に混合した後に造粒することでラクトース１０重量％、ラフィノース４．９重量％、ラクチュロース１０重量％、セロオリゴ糖２３重量％、キシロオリゴ糖２重量％、フラクトオリゴ糖３０重量％、イソマルトオリゴ糖１０重量％、ガラクトオリゴ糖１０重量％、ショ糖０．１重量％を含む実施例４の組成物を得た。
（２）評価
　実施例４の組成物を、便秘気味の５名（男性３名、女性２名）に１週間５ｇ/日ずつ摂取してもらい、便の回数、時間帯、状態、量についてアンケートを実施した。
　その結果、５人中４名が便の回数、状態に関して摂取しないときよりも改善されていると回答した。特に２名は量の増大の変化もみられた。 (Example 4)
(1) Preparation of composition The composition of Example 4 was prepared according to the following procedure.
100 g of lactose, 49 g of raffinose, 100 g of lactulose, 230 g of cellooligosaccharide, 20 g of xylooligosaccharide, 300 g of fructooligosaccharide, 100 g of isomaltoligosaccharide, 100 g of galactooligosaccharide and 1 g of sucrose are mixed well until granulated, and granulated. Wt%, raffinose 4.9 wt%, lactulose 10 wt%, cellooligosaccharide 23 wt%, xylooligosaccharide 2 wt%, fructooligosaccharide 30 wt%, isomaltoligosaccharide 10 wt%, galactooligosaccharide 10 wt%, sucrose 0. The composition of Example 4 containing 1% by weight was obtained.
(2) Evaluation The composition of Example 4 was ingested by 5 persons (3 males and 2 females) with constipation for 5 g / day a week. Carried out.
As a result, 4 out of 5 responded that the number of stools was improved compared to when they were not ingested. Two people in particular also showed changes in the amount of increase.
　本発明によれば、個人差、体調、年齢などで環境が異なる腸内細菌叢に対しても改善効果を得ることができる。 According to the present invention, it is possible to obtain an improvement effect on the intestinal bacterial flora whose environment varies depending on individual differences, physical condition, age, and the like.

Claims (12)

  1. 　対象となる腸内善玉菌の活性化に適する複数のオリゴ糖を選定し、該複数のオリゴ糖を前記腸内善玉菌の活性化に適する配合割合で組み合わせて腸内細菌叢に与えることを特徴とする腸内善玉菌の活性化方法。 Select a plurality of oligosaccharides suitable for the activation of the target enteric bacteria, and combine the plurality of oligosaccharides at a blending ratio suitable for the activation of the enteric bacteria to give the intestinal flora A method for activating good intestinal bacteria.
  2. 　前記複数のオリゴ糖が、ラクトース、ラフィノース、ラクチュロース、セロオリゴ糖、キシロオリゴ糖、フラクトオリゴ糖、イソマルトオリゴ糖及びガラクトオリゴ糖からなる群から選択される２種以上である請求項１記載の腸内善玉菌の活性化方法。 The intestinal good bacteria according to claim 1, wherein the plurality of oligosaccharides are two or more selected from the group consisting of lactose, raffinose, lactulose, cellooligosaccharide, xylooligosaccharide, fructooligosaccharide, isomaltoligosaccharide and galactooligosaccharide. Activation method.
  3. 　前記複数のオリゴ糖が、ラクトース、ラフィノース及びセロオリゴ糖の組み合わせである請求項１記載の腸内善玉菌の活性化方法。 The method for activating good enterobacteria according to claim 1, wherein the plurality of oligosaccharides is a combination of lactose, raffinose and cellooligosaccharide.
  4. 　前記複数のオリゴ糖が、ラフィノース、ラクチュロース及びセロオリゴ糖の組み合わせである請求項１記載の腸内善玉菌の活性化方法。 The method for activating good enterobacteria according to claim 1, wherein the plurality of oligosaccharides is a combination of raffinose, lactulose and cellooligosaccharide.
  5. 　前記複数のオリゴ糖が、ラクトース、ラフィノース、ラクチュロース及びセロオリゴ糖の組み合わせである請求項１記載の腸内善玉菌の活性化方法。 The method for activating good enterobacteria according to claim 1, wherein the plurality of oligosaccharides is a combination of lactose, raffinose, lactulose and cellooligosaccharide.
  6. 　前記複数のオリゴ糖が、ラクトース、ラフィノース、ラクチュロース、セロオリゴ糖、キシロオリゴ糖、フラクトオリゴ糖、イソマルトオリゴ糖及びガラクトオリゴ糖である請求項１記載の腸内善玉菌の活性化方法。 The method for activating good enterobacteria according to claim 1, wherein the plurality of oligosaccharides are lactose, raffinose, lactulose, cellooligosaccharide, xylooligosaccharide, fructooligosaccharide, isomaltoligosaccharide and galactooligosaccharide.
  7. 　対象となる腸内善玉菌の活性化に適する複数のオリゴ糖を選定し、該複数のオリゴ糖を前記腸内善玉菌の活性化に適する配合割合で組み合わせた混合物を含有することを特徴とする腸内善玉菌活性化組成物。 A plurality of oligosaccharides suitable for the activation of the target enteric bacteria are selected, and a mixture of the plurality of oligosaccharides combined at a blending ratio suitable for the activation of the enteric good bacteria is contained. Intestinal good bacteria activation composition.
  8. 　前記複数のオリゴ糖が、ラクトース、ラフィノース、ラクチュロース、セロオリゴ糖、キシロオリゴ糖、フラクトオリゴ糖、イソマルトオリゴ糖及びガラクトオリゴ糖からなる群から選択される２種以上である請求項７記載の腸内善玉菌活性化組成物。 The intestinal good bacteria activity according to claim 7, wherein the plurality of oligosaccharides are two or more selected from the group consisting of lactose, raffinose, lactulose, cellooligosaccharide, xylooligosaccharide, fructooligosaccharide, isomaltooligosaccharide and galactooligosaccharide. Composition.
  9. 　前記複数のオリゴ糖が、ラクトース、ラフィノース及びセロオリゴ糖の組み合わせである請求項７記載の腸内善玉菌活性化組成物。 The intestinal good bacteria activating composition according to claim 7, wherein the plurality of oligosaccharides is a combination of lactose, raffinose and cellooligosaccharide.
  10. 　前記複数のオリゴ糖が、ラフィノース、ラクチュロース及びセロオリゴ糖の組み合わせである請求項７記載の腸内善玉菌活性化組成物。 The intestinal good bacteria activating composition according to claim 7, wherein the plurality of oligosaccharides is a combination of raffinose, lactulose and cellooligosaccharide.
  11. 　前記複数のオリゴ糖が、ラクトース、ラフィノース、ラクチュロース及びセロオリゴ糖の組み合わせである請求項７記載の腸内善玉菌活性化組成物。 The intestinal good bacteria activating composition according to claim 7, wherein the plurality of oligosaccharides is a combination of lactose, raffinose, lactulose and cellooligosaccharide.
  12. 　前記複数のオリゴ糖が、ラクトース、ラフィノース、ラクチュロース、セロオリゴ糖、キシロオリゴ糖１、フラクトオリゴ糖、イソマルトオリゴ糖及びガラクトオリゴ糖である請求項７記載の腸内善玉菌活性化組成物。 The enteric good bacteria activating composition according to claim 7, wherein the plurality of oligosaccharides are lactose, raffinose, lactulose, cellooligosaccharide, xylooligosaccharide 1, fructooligosaccharide, isomaltooligosaccharide and galactooligosaccharide.
PCT/JP2012/060048 2011-04-15 2012-04-12 Method for activating good intestinal bacterium, and composition for activating good intestinal bacterium WO2012141256A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013509964A JP6328422B2 (en) 2011-04-15 2012-04-12 Intestinal good bacteria activation composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011-091362 2011-04-15
JP2011091362 2011-04-15

Publications (1)

Publication Number Publication Date
WO2012141256A1 true WO2012141256A1 (en) 2012-10-18

Family

ID=47009423

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/060048 WO2012141256A1 (en) 2011-04-15 2012-04-12 Method for activating good intestinal bacterium, and composition for activating good intestinal bacterium

Country Status (2)

Country Link
JP (2) JP6328422B2 (en)
WO (1) WO2012141256A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105535580A (en) * 2015-12-21 2016-05-04 上海善力健生物科技有限公司 A biological agent for improving human body intestinal floras and a preparing method thereof
JP2017502701A (en) * 2014-01-16 2017-01-26 アルヴィンド マリナース ラリ、 Fractionation of oligosaccharides from agricultural waste
JP2021536227A (en) * 2018-08-15 2021-12-27 ケンブリッジ グリコサイエンス エルティーディー New compositions, their use, and how they are formed
JP2022534154A (en) * 2020-04-29 2022-07-28 ネオ クレマー カンパニー リミテッド Functional food composition and cosmetic composition for improving immune function and improving skin condition containing galacto-oligosaccharide, or galacto-oligosaccharide and collagen tripeptide
US11771123B2 (en) 2019-08-16 2023-10-03 Cambridge Glycoscience Ltd Methods for treating biomass to produce oligosaccharides and related compositions
US11871763B2 (en) 2019-12-12 2024-01-16 Cambridge Glycoscience Ltd Low sugar multiphase foodstuffs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10175867A (en) * 1996-12-12 1998-06-30 Morinaga Milk Ind Co Ltd Bifidus bacteria multiplication accelerating composition and its use
JP2007330177A (en) * 2006-06-16 2007-12-27 Asahi Kasei Chemicals Corp Activator of enteric bacterium

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10175867A (en) * 1996-12-12 1998-06-30 Morinaga Milk Ind Co Ltd Bifidus bacteria multiplication accelerating composition and its use
JP2007330177A (en) * 2006-06-16 2007-12-27 Asahi Kasei Chemicals Corp Activator of enteric bacterium

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ASAKO HORIKAWA: "Oligo-To Kongobutsu ni yoru Benpi no Kanwa", JOURNAL OF JAPAN SOCIETY FOR LACTIC ACID BACTERIA, vol. 22, no. 2, 1 July 2011 (2011-07-01), pages 135 *
YOSHIYUKI MORISHITA: "Dietary Components Responsible for the Stability and Alteration of the Intestinal Microflora (2)", JOURNAL OF INTESTINAL MICROBIOLOGY, vol. 12, no. 2, 1999, pages 57 - 72 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502701A (en) * 2014-01-16 2017-01-26 アルヴィンド マリナース ラリ、 Fractionation of oligosaccharides from agricultural waste
CN105535580A (en) * 2015-12-21 2016-05-04 上海善力健生物科技有限公司 A biological agent for improving human body intestinal floras and a preparing method thereof
JP2021536227A (en) * 2018-08-15 2021-12-27 ケンブリッジ グリコサイエンス エルティーディー New compositions, their use, and how they are formed
JP7374991B2 (en) 2018-08-15 2023-11-07 ケンブリッジ グリコサイエンス エルティーディー Novel compositions, their uses, and methods of forming them
US11903399B2 (en) 2018-08-15 2024-02-20 Cambridge Glycoscience Ltd Compositions, their use, and methods for their formation
US11771123B2 (en) 2019-08-16 2023-10-03 Cambridge Glycoscience Ltd Methods for treating biomass to produce oligosaccharides and related compositions
US11871763B2 (en) 2019-12-12 2024-01-16 Cambridge Glycoscience Ltd Low sugar multiphase foodstuffs
JP2022534154A (en) * 2020-04-29 2022-07-28 ネオ クレマー カンパニー リミテッド Functional food composition and cosmetic composition for improving immune function and improving skin condition containing galacto-oligosaccharide, or galacto-oligosaccharide and collagen tripeptide
JP7212410B2 (en) 2020-04-29 2023-01-25 ネオ クレマー カンパニー リミテッド Functional food composition and cosmetic composition for improving immune function and improving skin condition containing galacto-oligosaccharide, or galacto-oligosaccharide and collagen tripeptide

Also Published As

Publication number Publication date
JPWO2012141256A1 (en) 2014-07-28
JP2018138580A (en) 2018-09-06
JP6328422B2 (en) 2018-05-23

Similar Documents

Publication Publication Date Title
JP2018138580A (en) Method for activating intestinal probiotic bacteria
Giacaman Sugars and beyond. The role of sugars and the other nutrients and their potential impact on caries
US7141554B2 (en) Method of treating irritable bowel syndrome
US20040161422A1 (en) Nutritional compositions comprising probiotics
JP4451879B2 (en) Use of isomalt as prebiotic
US20100322904A1 (en) Composition comprising bifidobacterium infantis and fructo- and galacto-oligosaccharides for the prevention of intestinal discomfort in infants
JP2013209396A (en) Composition and method for augmenting kidney function
EP2014181A2 (en) Compositions based on prebiotic and immunogenic ingredients for the prevention and treatment of gastroenteric disorders caused by dysbiosis and/or alterations of the normal intestinal flora
CN108935698A (en) A kind of alimentation composition preventing baby diarrhea disease and application
Sharma et al. Miraculous health benefits of prebiotics
WO2007114499A1 (en) Anti-fat-accumulation composition
JP6960988B2 (en) Preventive or ameliorating agent for exacerbation of insulin resistance
de Figueiredo et al. Advances and new perspectives in prebiotic, probiotic and symbiotic products for food nutrition and feed
KR100424660B1 (en) Vitamin-enriched nutritional food composition comprising Bacillus polyfermenticus KCCM 10104 effectively for prevention of intestinal disorders
WO2017057535A1 (en) Deoxycholic acid reduction agent
KR20050105669A (en) Probiotic composition
CA3157496A1 (en) Dietary fiber compositions with psyllium and methods of use
A Radwan et al. Effect of probiotic fermented camel milk containing Oat milk on hyperglycemia in streptozotocin-induced diabetic rats
US8993639B2 (en) Compound and method for treatment of gastroesophageal reflux
Fu et al. Efficacy and safety of xylooligosacchrides
JP2003052334A (en) Diet food
JP6112493B2 (en) Composition
WO2023205762A9 (en) Methods and compositions for slowing diabetes development or reducing a risk of diabetes
DE202022001692U1 (en) Preparation of an innovative three-component powder mixture with a tribiotic active principle
EP2931055B1 (en) Cocoa-containing food composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12770857

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2013509964

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12770857

Country of ref document: EP

Kind code of ref document: A1